TY - JOUR
T1 - Cancer Moonshot Immuno-Oncology Translational Network (IOTN)
T2 - Accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer
AU - Annapragada, Ananth
AU - Sikora, Andrew
AU - Bollard, Catherine
AU - Conejo-Garcia, Jose
AU - Cruz, Conrad Russell
AU - Demehri, Shadmehr
AU - Demetriou, Michael
AU - Demirdjian, Levon
AU - Fong, Lawrence
AU - Horowitz, Mary
AU - Hutson, Alan
AU - Kadash-Edmondson, Kathryn
AU - Kufe, Donald
AU - Lipkin, Steven
AU - Liu, Song
AU - McCarthy, Claire
AU - Morgan, Martin
AU - Morris, Zachary
AU - Pan, Yang
AU - Pasquini, Marcelo
AU - Schoenberger, Stephen
AU - Van Allen, Eliezer
AU - Vilar, Eduardo
AU - Xing, Yi
AU - Zha, Wenjuan
AU - Odunsi, Adekunle
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
PY - 2020/6/17
Y1 - 2020/6/17
N2 - Despite regulatory approval of several immune-based treatments for cancer in the past decade, a number of barriers remain to be addressed in order to fully harness the therapeutic potential of the immune system and provide benefits for patients with cancer. As part of the Cancer Moonshot initiative, the Immuno-Oncology Translational Network (IOTN) was established to accelerate the translation of basic discoveries to improve immunotherapy outcomes across the spectrum of adult cancers and to develop immune-based approaches that prevent cancers before they occur. The IOTN currently consists of 32 academic institutions in the USA. By leveraging cutting-edge preclinical research in immunotherapy and immunoprevention, open data and resource sharing, and fostering highly collaborative team science across the immuno-oncology ecosystem, the IOTN is designed to accelerate the generation of novel mechanism-driven immune-based cancer prevention and therapies, and the development of safe and effective personalized immuno-oncology approaches.
AB - Despite regulatory approval of several immune-based treatments for cancer in the past decade, a number of barriers remain to be addressed in order to fully harness the therapeutic potential of the immune system and provide benefits for patients with cancer. As part of the Cancer Moonshot initiative, the Immuno-Oncology Translational Network (IOTN) was established to accelerate the translation of basic discoveries to improve immunotherapy outcomes across the spectrum of adult cancers and to develop immune-based approaches that prevent cancers before they occur. The IOTN currently consists of 32 academic institutions in the USA. By leveraging cutting-edge preclinical research in immunotherapy and immunoprevention, open data and resource sharing, and fostering highly collaborative team science across the immuno-oncology ecosystem, the IOTN is designed to accelerate the generation of novel mechanism-driven immune-based cancer prevention and therapies, and the development of safe and effective personalized immuno-oncology approaches.
KW - immunity
KW - immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85086691799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086691799&partnerID=8YFLogxK
U2 - 10.1136/jitc-2020-000796
DO - 10.1136/jitc-2020-000796
M3 - Review article
C2 - 32554617
AN - SCOPUS:85086691799
SN - 2051-1426
VL - 8
JO - Journal for immunotherapy of cancer
JF - Journal for immunotherapy of cancer
IS - 1
M1 - e000796
ER -